Direct to Consumer Sales and Distribution Plan

Belluscura PLC

("Belluscura" or the "Company")

Belluscura Launches Direct to Consumer Sales and Distribution Plan

New Direct to Consumer and Partnership Distributor Plan expected to increase revenue and gross profits

LONDON, U.K. AND PLANO, TX, U.S. (30 June 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has commenced selling its X-PLOR oxygen concentrators direct to consumers ("DTC") from the following website: www.xploroxygen.com. 

The Company has also started a new partnership distribution programme directed at increasing the availability of portable oxygen concentrators to small, local durable medical equipment providers who are experiencing considerable delays in the wait for portable concentrators. Both initiatives are expected to significantly expand our distribution network across the US and to increase revenue and profits. A brochure containing information on the X-PLOR oxygen concentrator can be found here http://www.rns-pdf.londonstockexchange.com/rns/7145Q_1-2022-6-29.pdf.

Robert Rauker, CEO of Belluscura plc, said: "Selling our products direct to consumers allow us to generate higher revenue and increased profits over the longer term. In addition, our new Partnership Distribution Plan is directed at smaller distributors, further expanding our distribution network throughout the US."

Adam Reynolds, Chairman of Belluscura plc, said "Both the launch of direct to consumers sales along with making our product available to the hundreds of smaller, local supplemental oxygen providers, creates significant opportunities for Belluscura." 

For further information please contact:

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.